Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy

Improved risk stratification of patients suspected of prostate cancer prior to biopsy continues to be an unmet clinical need. ExoDx Prostate (IntelliScore) “EPI” is a non-invasive urine test utilizing RNA from exosomes to provide a risk score that correlates with the likelihood of finding high grade...

Descripción completa

Detalles Bibliográficos
Autores principales: Kretschmer, Alexander, Kajau, Holger, Margolis, Eric, Tutrone, Ronald, Grimm, Tobias, Trottmann, Matthias, Stief, Christian, Stoll, Georg, Fischer, Christian A., Flinspach, Claudia, Albrecht, Anja, Meyer, Lisa, Priewasser, Tina, Enderle, Daniel, Müller, Romy, Torkler, Phillipp, Alter, Jason, Skog, Johan, Noerholm, Mikkel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938406/
https://www.ncbi.nlm.nih.gov/pubmed/35314720
http://dx.doi.org/10.1038/s41598-022-08608-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938406/
https://www.ncbi.nlm.nih.gov/pubmed/35314720
http://dx.doi.org/10.1038/s41598-022-08608-z

Ejemplares similares